检索结果-南通市图书馆

Simple and robust 3D MINFLUX excitation with a variable phase plate

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Light(Science & Applications) 2024年第7期13卷 1354-1363页

作者： takahiro Deguchi Jonas Ries European Molecular Biology Laboratory Cell Biology and BiophysicsHeidelbergGermany. Max Perutz Labs Vienna Biocenter Campus(VBC)ViennaAustria. University of Vienna Center for Molecular BiologyDepartment of Structural and Computational BiologyViennaAustria. University of Vienna Faculty of PhysicsViennaAustria

MINFLUX has achieved extraordinary resolution in superresolution imaging and single fluorophore *** is based on localizing single fluorophores by rapid probing with a patterned beam that features a local intensity *** implementations,however,are complex and expensive and are limited in speed and ***,we show that a combination of an electro-optical modulator with a segmented birefringent element such as a spatial light modulator produces a variable phase plate for which the phase can be scanned on the MHz *** or top-hat phase patterns generate high-contrast compact excitation point-spread functions for MINFLUX localization in the x,y,and z-direction,respectively,which can be scanned across a fluorophore within a microsecond,switched within 60 microseconds and alternated among different excitation *** discuss how to compensate for non-optimal performance of the components and present a robust 3D and multi-color MINFLUX excitation module,which we envision as an integral component of a high-performance and cost-effective open-source MINFLUX.

关键词： excitation phase switched

Stage at diagnosis of colorectal cancer through diagnostic route:Who should be screened?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2024年第10期30卷 1368-1376页

作者： Nobukazu Agatsuma takahiro Utsumi Yoshitaka Nishikawa takahiro Horimatsu Takeshi Seta Yukitaka Yamashita Yukari Tanaka takahiro Inoue Yuki Nakanishi takahiro Shimizu Mikako Ohno Akane Fukushima Takeo Nakayama Hiroshi Seno Department of Gastroenterology and Hepatology Kyoto University Graduate School of MedicineKyoto 606-8507Japan Department of Gastroenterology and Hepatology Japanese Red Cross Wakayama Medical CenterWakayama 640-8558Japan Department of Health Informatics Kyoto University School of Public HealthKyoto 606-8501Japan Institute for Advancement of Clinical and Translational Science(iACT) Kyoto University HospitalKyoto 606-8507Japan Medical Support Section Medical Affairs DivisionKyoto University HospitalKyoto 606-8507Japan

BACKGROUND Colorectal cancer(CRC)is a global health concern,with advanced-stage diagnoses contributing to poor *** efficacy of CRC screening has been well-established;nevertheless,a significant proportion of patients remain unscreened,with>70%of cases diagnosed outside *** identifying specific subgroups for whom CRC screening should be particularly recommended is crucial owing to limited resources,the association between the diagnostic routes and identification of these subgroups has been less *** the Japanese cancer registry,the diagnostic routes for groups discovered outside of screening are primarily categorized into those with comorbidities found during hospital visits and those with CRC-related *** To clarify the stage at CRC diagnosis based on diagnostic *** We conducted a retrospective observational study using a cancer registry of patients with CRC between January 2016 and December 2019 at two *** diagnostic routes were primarily classified into three groups:Cancer screening,follow-up,and *** early-stage was defined as Stages 0 or *** and univariate logistic regressions were exploited to determine the odds of early-stage diagnosis in the symptomatic and cancer screening groups,referencing the follow-up *** adjusted covariates were age,sex,and tumor *** Of the 2083 patients,715(34.4%),1064(51.1%),and 304(14.6%)belonged to the follow-up,symptomatic,and cancer screening groups,*** the 2083 patients,CRCs diagnosed at an early stage were 57.3%(410 of 715),23.9%(254 of 1064),and 59.5%(181 of 304)in the follow-up,symptomatic,and cancer screening groups,*** symptomatic group exhibited a lower likelihood of early-stage diagnosis than the follow-up group[P<0.001,adjusted odds ratio(aOR),0.23;95%confidence interval(95%CI):0.19-0.29].The likelihood of diagnosis at an early stage was similar between the follow-up and cancer screening gro

关键词： Colorectal neoplasms Cancer registry Diagnostic route Cancer screening Stage at diagnosis

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第40期22卷 8967-8977页

作者： Issei Saeki Naoki Yamamoto takahiro yamasaki Taro Takami Masaki Maeda Koichi Fujisawa Takuya Iwamoto Toshihiko Matsumoto Isao Hidaka Tsuyoshi Ishikawa Koichi Uchida Kenji Tani Isao Sakaida Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Yamaguchi 755-8505 Japan Yamaguchi University Health Administration Center Yamaguchi 755-8511 Japan Department of Oncology and Laboratory Medicine Yamaguchi University Graduate School of Medicine Yamaguchi 755-8505 Japan Department of Human Nutrition Faculty of Nursing and Human Nutrition Yamaguchi 755-8502 Japan Center of Research and Education for Regenerative Medicine Yamaguchi University Graduate School of Medicine Yamaguchi Prefectural University Yamaguchi 755-8505 Japan Department of Veterinary Surgery Joint Faculty of Veterinary Medicine Yamaguchi University Yamaguchi 755-8511 Japan

AIM To evaluate the inhibitory effects of deferasirox(DFX) against hepatocellular carcinoma(HCC) through basic and clinical *** In the basic study, the effect of DFX was investigated in three hepatoma cell lines(Hep G2, Hep3 B, and Huh7), as well as in an N-nitrosodiethylamine-induced murine HCC model. In the clinical study, six advanced HCC patients refractory to chemotherapy were enrolled. The initial dose of DFX was 10 mg/kg per day and was increased by 10 mg/kg per day every week, until the maximum dose of 30 mg/kg per day. The duration of a single course of DFX therapy was 28 consecutive days. In the event of dose-limiting toxicity(according to the Common Terminology Criteria for Adverse Events v.4.0), DFX dose was *** Administration of DFX inhibited the proliferation of hepatoma cell lines and induced the activation of caspase-3 in a dose-dependent manner in vitro. In the murine model, DFX treatment significantly suppressed the development of liver tumors(P < 0.01), and significantly upregulated the mR NA expression levels of hepcidin(P < 0.05), transferrin receptor 1(P < 0.05), and hypoxia inducible factor-1α(P < 0.05) in both tumor and non-tumor tissues, compared with control mice. In the clinical study, anorexia and elevated serum creatinine were observed in four and all six patients, respectively. However, reduction in DFX dose led to decrease in serum creatinine levels in all patients. After the first course of DFX, one patient discontinued the therapy. We assessed the tumor response in the remaining five patients; one patient exhibited stable disease, while four patients exhibited progressive disease. The one-year survival rate of the six patients was 17%.CONCLUSION We demonstrated that DFX inhibited HCC in the basic study, but not in the clinical study due to dose-limiting toxicities.

关键词：肝肿瘤 Hepatocellular 癌先进舞台 Iron-chelator Deferasirox

Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第32期22卷 7252-7263页

作者： Taro Takami takahiro yamasaki Issei Saeki Toshihiko Matsumoto Yutaka Suehiro Isao Sakaida Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Department of Oncology and Laboratory Medicine Yamaguchi University Graduate School of Medicine

Hepatocellular carcinoma(HCC) is one of the deadliest cancers in the world and is associated with a high risk of recurrence. The development of a wide range of new therapies is therefore essential. In this study, from the perspective of supportive therapy for the prevention of HCC recurrence and preservation of liver function in HCC patients, we surveyed a variety of different therapeutic agents. We show that branched chain amino acids(BCAA) supplementation and late evening snack with BCAA, strategies that address issues of protein-energy malnutrition, are important for liver cirrhotic patients with HCC. For chemoprevention of HCC recurrence, we show that viral control after radical treatment is important. We also reviewed the therapeutic potential of antiviral drugs, sorafenib, peretinoin, iron chelators. Sorafenib is a kinase inhibitor and a standard therapy in the treatment of advanced HCC. Peretinoin is a vitamin A-like molecule that targets the retinoid nuclear receptor to induce apoptosis and inhibit tumor growth in HCC cells. Iron chelators, such as deferoxamine and deferasirox, act to prevent cancer cell growth. These chelators may have potential as combination therapies in conjunction with peretinoin. Finally, we review the potential inhibitory effect of bone marrow cells on hepatocarcinogenesis.

关键词： Hepatocellular carcinoma Liver cirrhosis Branched-chain amino acids Late evening snack Iron chelators Bone marrow cells

Treatment strategies for advanced hepatocellular carcinoma:Sorafenib vs hepatic arterial infusion chemotherapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2018年第9期10卷 571-584页

作者： Issei Saeki takahiro yamasaki Masaki Maeda Takuro Hisanaga Takuya Iwamoto Koichi Fujisawa Toshihiko Matsumoto Isao Hidaka Yoshio Marumoto Tsuyoshi Ishikawa Naoki Yamamoto Yutaka Suehiro Taro Takami Isao Sakaida Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of MedicineYamaguchi 755-8505Japan Department of Oncology and Laboratory Medicine Yamaguchi University Graduate School of MedicineYamaguchi 755-8505Japan Department of Medical Education Yamaguchi University Graduate School of MedicineYamaguchi 755-8505Japan Center of Research and Education for Regenerative Medicine Yamaguchi University Graduate School of MedicineYamaguchi755-8505Japan Center for Clinical Research Yamaguchi University HospitalYamaguchi 755-8505Japan Yamaguchi University Health Administration Center Yamaguchi 753-8511Japan

Sorafenib is used worldwide as a first-line standardsystemic agent for advanced hepatocellular carcinoma(HCC) on the basis of the results of two large-scale Phase Ⅲ trials. Conversely,hepatic arterial infusion chemotherapy(HAIC) is one of the most recommended treatments in Japan. Although there have been no randomized controlled trials comparing sorafenib with HAIC,several retrospective analyses have shown no significant differences in survival between the two therapies. Outcomes are favorable for HCC patients exhibiting macroscopic vascular invasion when treated with HAIC rather than sorafenib,whereas in HCC patients exhibiting extrahepatic spread or resistance to transcatheter arterial chemoembolization,good outcomes are achieved by treatment with sorafenib rather than HAIC. Additionally,sorafenib is generally used to treat patients with Child-Pugh A,while HAIC is indicated for those with either Child-Pugh A or B. Based on these findings,we reviewed treatment strategies for advanced HCC. We propose that sorafenib might be used as a first-line treatment for advanced HCC patients without macroscopic vascular invasion or Child-Pugh A,while HAIC is recommended for those with macroscopic vascular invasion or Child-Pugh A or B. Additional research is required to determine the best second-line treatment for HAIC non-responders with Child-Pugh B through future clinical trials.

关键词： Treatment strategy Hepatic arterial infusion chemotherapy Sorafenib Hepatocellular carcinoma

Enzyme-linked immunosorbent assay of 3 Screen Islet Cell Autoantibody in patients with autoimmune thyroid disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Diabetes 2024年第5期15卷 935-944页

作者： Eiji Kawasaki Hidekazu Tamai takahiro Fukuyama Yoko Sagara Ryutaro Hidaka Aira Uchida Masayuki Tojikubo Narihito Tatsumoto Yuko Akehi Yuji Hiromatsu The Diabetes Thyroid and Endocrine CenterShin-Koga HospitalKurume 830-8577Japan

BACKGROUND In recent years,the emergence of multiplex technology that can simultaneously measure multiple anti-islet autoantibodies has become particularly valuable for the staging and early diagnosis of immune-mediated type 1 diabetes(T1D).While it has been established that 20%-30%of T1D patients suffer from autoimmune thyroid disease(AITD),there is limited available data regarding the presence of anti-islet autoantibodies in AITD *** commercially available anti-islet autoantibodies,glutamic acid decarboxylase 65 autoantibodies(GADAs)are often the first marker measured in general clinical *** To investigate the frequency of anti-islet autoantibodies in AITD *** Our study involved four hundred ninety-five AITD patients,categorized into three distinct groups:AITD with T1D(n=18),AITD with phenotypic type 2 diabetes(T2D)(n=81),and AITD without diabetes(n=396),and the enzyme-linked immunosorbent assay(ELISA)was employed to determine the frequencies of 3 Screen Islet Cell Autoantibody(3 Screen ICA),GADA,insulinoma-associated antigen-2 autoantibodies(IA-2As),and zinc transporter 8 autoantibodies(ZnT8As)within these *** The frequency of 3 Screen ICA in AITD patients with T1D,T2D,and those without diabetes were 88.9%,6.2%,and 5.1%,respectively,with no significant difference seen between the latter two ***,the frequency of 3 Screen ICA was 11.1%higher in AITD patients with T1D,1.3%higher in AITD patients with T2D,and 1.1%higher in AITD patients without diabetes compared to GADA,***,12.5%,20.0%,and 20.0%of the 3 Screen ICA-positive patients were negative for ***,1.3%of the AITD patients who tested negative for 3 Screen ICA in both the AITD with T2D and non-diabetic AITD groups were found to be positive for individual *** the 3 Screen ICA-positive patients,there was a significantly higher proportion of individuals with multiple autoantibodies in AITD patients with T1D com

关键词： Anti-islet autoantibodies Autoimmune thyroid disease Real-world practice Retrospective study Type 1 diabetes

Electron scattering by Friedel oscillations in carbon nanotubes

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Nano Research 2022年第2期15卷 889-897页

作者： Takumi Inaba takahiro Morimoto Satoshi Yamazaki Toshiya Okazaki CNT-Application Research Center National Institute of Advanced Industrial Science and TechnologyTsukuba 305-8565Japan Research Association of High-Throughput Design and Development for Advanced Functional Materials Tsukuba 305-8565Japan

Multi-walled carbon nanotube networks were confirmed to exhibit a linear decrease in resistivity with increasing temperature from 100 to above 400 *** linearity was explained using a defect scattering model that involved Friedel oscillations(that is,electron-electron interactions).The applicability of this model,which was originally proposed for graphene,to carbon nanotubes was assessed based on a comparison of various experimental *** in the slopes of the resistivity-temperature plots following the introduction of defects,as well as an effect of charge concentration on the slope were key predictions of this *** results obtained from few-walled carbon nanotube networks are also *** the literature,linear resistivity-temperature plots were obtained from other graphene derivatives,indicating that the linearity originates from the hexagonal symmetry of these *** present work also indicated a relationship between the appearance of linearity and negative magnetoresistance above 100 *** on a mechanism incorporating scattering in association with Friedel oscillations and conventional electron conduction models,the universality of resistivity-temperature plots obtained from carbon nanotube networks is introduced.

关键词： carbon nanotube electron transport electron-electron interaction Friedel oscillations magnetoresistance

Removal of hexavalent chromium from water by Z-scheme photocatalysis using TiO_(2)(rutile)nanorods loaded with Au core-Cu_(2)0 shell particles

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Environmental Sciences 2022年第5期34卷 173-189页

作者： Sayaka Yanagida Takumi Yajima takahiro Takei Nobuhiro Kumada Center for Crystal Science and Technology University of YamanashiKofu 400-8511Japan Advanced Materials Development Sector Tokyo Metropolitan Industrial Technology Research Institute2-4-10AomiKoto-kuTokyo 135-0064Japan

All-solid-state Z-scheme photocatalysts,containing Cu_(2)O,TiO_(2)(rutile),and Au as the elec-tron mediator,were prepared and applied to the reduction of Cr(Ⅵ)in aqueous *** Cu_(2)O-Au-TiO_(2) composites were prepared by loading Au core-Cu_(2)O shell hemisphere particles on TiO_(2)(rutile)nanorods using a two-step photocatalytic deposition ***-der ultraviolet-visible(UV-vis)light illumination,the Cu_(2)O-Au-TiO_(2) composites exhibited higher photocatalytic Cr(Ⅵ)reduction activities than those exhibited by single TiO_(2)(rutile)and Cu_(2)*** this reaction,a precipitate containing Cr,which was considered to be Cr(OH)_(3),was deposited site-selectively on the Au core-Cu_(2)O shell particles of the composites,indi-cating that the reduction site of the composite was Cu_(2)O,and the reaction proceeded accord-ing to the *** Cu_(2)O-Au-TiO_(2) composites also exhibited photocatalytic activity under visible light *** oxidation state of Cu in the Cu_(2)O-Au-TiO_(2) composite gradually changed from Cu(Ⅰ)to Cu(Ⅱ)during the photocatalytic Cr(Ⅵ)*** the composite maintained its high photocatalytic performance even after *** role of Au in the Cu_(2)O-Au-TiO_(2) composite was examined by comparing the properties of the Cu_(2)O-Au-TiO_(2) composite with those of the Cu_(2)O-TiO_(2) composite prepared via direct Cu_(2)O deposition on TiO_(2).

关键词： Cu_(2)O TiO_(2)(rutile) Z-scheme Photocatalyst Chromium

Goblet cell carcinoid of the appendix:Six case reports

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2024年第22期12卷 5217-5224页

作者： Toshiaki Toshima Ryo Inada Shinya Sakamoto Eri Takeda takahiro Yoshioka Kento Kumon Naoki Mimura Nobuo Takata Motoyasu Tabuchi Kazuyuki Oishi Takuji Sato Kenta Sui Takehiro Okabayashi Kazuhide Ozaki Toshio Nakamura Yuichi Shibuya Manabu Matsumoto Jun Iwata Department of Gastroenterological Surgery Kochi Health Sciences CenterKochi 781-8555Japan Department of Diagnostic Pathology Kochi Health Sciences CenterKochi 781-8555Japan

BACKGROUND Goblet cell carcinoid(GCC)of the appendix is a rare tumor characterized by neuroendocrine and adenocarcinoma *** preoperative diagnosis is very difficult,with most patients complaining mainly of abdominal *** tomography shows swelling of the appendix,so diagnosis is usually made incidentally after appendectomy based on a preoperative diagnosis of *** if a patient undergoes preoperative colonoscopy,accurate endoscopic diagnosis is very difficult because GCC shows a submucosal growth pattern with invasion of the appendiceal *** SUMMARY Between 2017 and 2022,6 patients with GCC were treated in our *** presenting complaint for 5 of these 6 patients was abdominal *** 5 patients underwent appendectomy,including 4 for a preoperative diagnosis of appendicitis and the other for diagnosis and treatment of an appendiceal *** sixth patient presented with vomiting and underwent ileocecal resection for GCC diagnosed from preoperative *** 2 patients with GCC underwent colonoscopy,no neoplastic changes were *** of the six patients showed lymph node metastasis on pathological *** of the last followup(median:15 mo),all cases remained alive without *** As preoperative diagnosis of GCC is difficult,this possibility must be considered during surgical treatments for presumptive appendicitis.

关键词： Goblet cell carcinoid Appendix Preoperative diagnosis Endoscopic diagnosis Surgical treatment Case report